TTP LabTech has announced that Cancer Research UK has recently purchased an Acumen eX3 microplate cytometer to run an RNAi whole genome to identify cytotoxic survival regulators. “Our extended trial of the Acumen eX3 demonstrated it met all of [our] needs. In the immediate future it will enable us to perform very complicated assays measuring
20-30 cell cycle related parameters for every cell in every well of every plate” said Mike Howell of Cancer Research UK’s London Research Institute. “In the longer term we can see applications across a whole range of assays, species and cell types including multiparametric analysis of mixed cell populations, wound healing assays and cell adhesion assays.”